Doherty Installed as President of the International Association of Endocrine Surgeons

Gerard M. Doherty, MD, was installed as president of the International Association of Endocrine Surgeons (IAES) at the 47th World Congress of Surgery of the International Society of Surgery in Basel, Switzerland.

The IAES is a forum for the exchange of views of those who are involved in expanding the frontiers of endocrine surgery whether by clinical experience, laboratory investigation or in any other way. The IAES fulfills these aims, and is a proud member society in the International Society of Surgery (ISS/SIC). As president, Doherty will carry out the vision of the IAES. His term ends in 2019.

Gerard M. Doherty, MD
Gerard M. Doherty, MD

Gerard M. Doherty, MD
Moseley Professor of Surgery, Harvard Medical School
Surgeon-in-Chief, Brigham Health & Dana-Farber Cancer Institute
Crowley Family Distinguished Chair, Department of Surgery, Brigham and Women’s Hospital

Gerard M. Doherty, MD, an acclaimed endocrine surgeon, is a graduate of Holy Cross and the Yale School of Medicine. He completed residency training at UCSF, including medical staff fellowship at the National Cancer Institute.

Dr. Doherty joined Washington University School of Medicine in 1993, and became professor of surgery in 2001. In 2002 he became head of General Surgery and the Norman W. Thompson Professor of Surgery at the University of Michigan, where he also served as the General Surgery program director and vice chair of the Department of Surgery.

From 2012 to 2016, Dr. Doherty was the James Utley Professor and chair of the Department of Surgery at Boston University School of Medicine and surgeon-in-chief at Boston Medical Center before becoming Moseley Professor of Surgery at Harvard Medical School and surgeon-in-chief at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

He has devoted substantial effort to medical student and resident education policy. His bibliography includes over 300 peer-reviewed articles, reviews and book chapters, and several edited books.

He currently serves as President of the International Association of Endocrine Surgeons, Past-President of the American Association of Endocrine Surgeons and Reviews Editor of JAMA Surgery. He is a director of the Surgical Oncology Board of the American Board of Surgery.

Raphael Bueno, MD, Appointed Inaguraul Fredric G. Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research at Brigham and Women’s Hospital

Raphael Bueno, MD, has been appointed the Inaugural Fredric G. Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research at Brigham and Women’s Hospital.

Raphael Bueno MD Headshot
Raphael Bueno, MD

Raphael Bueno, MD
Fredric G. Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research, Brigham and Women’s Hospital
Chief of Thoracic Surgery, Brigham and Women’s Hospital
Co-Director, Lung Center, Brigham and Women’s Hospital
Professor of Surgery, Harvard Medical School

Raphael Bueno, MD, is chief of thoracic surgery at Brigham and Women’s Hospital (BWH) and professor of surgery at Harvard Medical School. He completed his bachelor’s degree at Harvard College and medical training at Harvard Medical School/Massachusetts Institute of Technology. He subsequently trained in general surgery at BWH and thoracic surgery at Massachusetts General Hospital, and joined the BWH thoracic faculty in 1996. Over the past 21 years, Bueno has developed robust clinical and research portfolios at BWH.

His clinical focus is management of thoracic malignancies, including mesothelioma, lung cancer, and esophageal cancer. His main research interests center on the molecular events that lead to malignancy in mesothelioma and lung cancer. Specifically, Bueno focuses on developing biomarkers for diagnosis, prognosis, and predicting therapy in malignant pleural mesothelioma and lung cancer. His research also includes tumor sequencing and identification of targetable pathways. He runs a molecular biology lab at the George W. Thorn Medical Research Building and has been funded for almost two decades by the National Cancer Institute, Department of Defense, foundations and industry grants. He also invented, patented, and licensed several algorithms and medical devices for patient care. Bueno has also invented and continues to develop several novel surgical procedures.

Bueno is a member of numerous prestigious national and international professional societies. He has been an invited lecturer at teaching hospitals and universities around the country and internationally. At BWH, he has built the largest division of thoracic surgery in the US, with 21 faculty members and five affiliated network sites in New England, and co-founded the BWH Lung Center. Bueno continues to push the boundaries of what is possible in patient care.

Adam S. Kibel, MD, Appointed Elliott Carr Cutler Professor of Surgery in Urology at Harvard Medical School

Adam S. Kibel, MD, has been appointed the Elliott Carr Cutler Professor of Surgery in Urology at Harvard Medical School.

Adam S. Kibel, MD Headshot
Adam S. Kibel, MD


Adam S. Kibel, MD

Chief of Urology, Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center
Elliott Carr Cutler Professor of Surgery in Urology, Harvard Medical School

Adam S. Kibel, MD, is chief of Urology at Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center. He is the Elliot Carr Cutler Professor of Surgery in Urology at Harvard Medical School and serves as chairman of the Harvard Program in Urology (Longwood). Dr. Kibel received his undergraduate and medical degrees from Cornell University, completed a residency at the Harvard Urology Program and a fellowship at the Brady Urologic Institute at Johns Hopkins.

With a practice focused on minimally invasive treatments for urologic cancers, Dr. Kibel has been listed as one of America’s Top Doctors by Castle Connolly and named a top urologist by Boston Magazine. The author of over 250 peer-reviewed publications, Dr. Kibel’s research focuses on the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease, and improved imaging of patients with urologic malignancies. His research has been supported by the National Cancer Institute, Department of Defense, American Cancer Society, American College of Surgeons and the American Foundation for Urologic Disease.